HEALTH

Sustained Control with New mAb for Myasthenia Gravis

SAVANNAH, GEORGIA – The investigational monoclonal antibody nipocalimab (Johnson & Johnson) is associated with significant improvement in patients with generalized myasthenia gravis (gMG) over a 24-week period, according to topline results from the phase 3 VIVACITY-MG3 study. The VIVACITY-MG3 trial is the first registrational study of a neonatal fragment crystallizable receptor (FcRn) blocker to show …

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button